Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Election of New Director
On October 8, 2019, the Board of Directors, or the Board, of Ziopharm Oncology, Inc., or the Company, appointed Christopher Bowden, MD, as a director of the Company to fill an existing vacancy on the Board. Dr. Bowden will serve as a director until the Company’s 2020 Annual Meeting of Stockholders and until such time as his successor is duly elected and qualified, or until his earlier death, resignation or removal. It is contemplated that Dr. Bowden may serve on certain committees of the Company’s Board in the future, but no such committee appointments have been made at this time.
Dr. Bowden, 58, has been the chief medical officer of Agios Pharmaceuticals, Inc. since May 2014. Prior to joining Agios, Dr. Bowden was vice president product development oncology, franchise lead (Signaling Group) at Genentech for eight years. From 2003 to 2006, Dr. Bowden was the executive director for EMEA (Europe, Middle East, Africa) regions for Bristol-Myers Squibb Company. Earlier, Dr. Bowden held positions of increasing responsibility in oncology clinical development,Phases I-III at Pharmacia Corporation and Janssen Pharmaceutical, Inc. Prior to his industry experience, Dr. Bowden was on the oncology faculty at the University of Virginia Health Science Center. Dr. Bowden serves on the Board of Directors of Miragen Therapeutics, Inc. Dr. Bowden received his M.D. from Hahnemann University School of Medicine followed by internal medicine training at Roger Williams Medical Center and the Providence VA Medical Center, Rhode Island. He completed his medical oncology fellowship at the National Cancer Institute Medicine Branch. Dr. Bowden is board certified in internal medicine and medical oncology.
Dr. Bowden will be compensated in accordance with the Company’s standard compensation arrangements fornon-employee directors, which are described in greater detail in the Company’s definitive proxy statement on Schedule 14A relating to its 2019 Annual Meeting of Stockholders, which was filed with the Securities and Exchange Commission, or the Commission, on April 29, 2019.
In connection with his appointment, the Company will enter into its standard form of indemnity agreement with Dr. Bowden, the form of which was filed as Exhibit 99.1 to the Company’s Current Report onForm 8-K filed with the Commission on January 31, 2013. Dr. Bowden was not selected as a director pursuant to any arrangements or understandings with the Company or with any other person and there are no related party transactions between Dr. Bowden and the Company that would require disclosure underItem 404(a) of Regulation S-K.
